Janssen’s nasal spray for depression recommended for approval by FDA
TITUSVILLE, N.J. — The Janssen Pharmaceutical Cos. of Johnson & Johnson announced this week that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted that data support the favorable benefit-risk profile of Spravato (esketamine) nasal spray CIII for adults living with treatment-resistant depression. Spravato is
